Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome

被引:28
作者
Jiao, Zonglin [1 ]
Cao, Shoubo [2 ]
Li, Jianhua [3 ,4 ]
Hu, Nan [5 ]
Gong, Yinghui [1 ]
Wang, Linduo [1 ]
Jin, Shi [4 ,6 ]
机构
[1] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[2] Linyi Peoples Hosp, Dept Med & Radiat Oncol, Linyi, Shandong, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Neurosurg, Shenzhen, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[5] Heilongjiang Agr Reclamat Bur Gen Hosp, Dept Oncol, Harbin, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Canc Hosp,Dept Med Oncol, Shenzhen, Peoples R China
关键词
lung cancer; carcinoembryonic antigen; prognosis; stage I; stage II; stage III; CARCINOEMBRYONIC ANTIGEN LEVEL; INDICATE POOR-PROGNOSIS; TUMOR-MARKERS; CYFRA; 21-1; CARCINOMA; COMBINATION; RECURRENCE; DIAGNOSIS; SURGERY; NSE;
D O I
10.3389/fmolb.2021.686313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Serum carcinoembryonic antigen (CEA), a classic tumour marker, is widely used in lung cancer in clinical practice. Nevertheless, few studies have elucidated the influence of dynamic changes in CEA in the perioperative phases, as a prognostic indicator, on lung cancer prognosis. Methods: This retrospective cohort analysis included consecutive patients with stage I-III lung cancer who underwent curative resection between December 2010 and December 2014. The patients were grouped into three cohorts: group A included patients with normal preoperative CEA, group B included patients with elevated preoperative CEA but normal postoperative CEA, and group C included patients with elevated preoperative and postoperative CEA. Five-year overall survival (OS) was estimated by Kaplan-Meier analysis (log-rank test). Multivariate analyses were performed with Cox proportional hazard regression. Results: A total of 1662 patients with stage I-III lung cancer were enrolled in our study. Patients with normal preoperative CEA had 15.9 and 20.1% better 3- and 5-year OS rates than the cohort with elevated preoperative CEA (p < 0.001). Furthermore, group C had 36.0 and 26.6% lower 5-year OS rates (n = 74, 32.4%) than group A (n = 1188, 68.4%) and group B (n = 139, 59.0%) (p < 0.001). Group B had poorer OS than group A (p = 0.016). For patients with different pathological TNM stages, subgroup analyses showed that group C had the shortest OS in stages I and II (p < 0.05), and patients with a post-preoperative CEA increment had poorer OS than those without an increment (p = 0.029). Multivariate analyses suggested that group C (HR = 2.0, 95% CI, 1.5-2.7, p < 0.001) rather than the group with normalized postoperative CEA (HR = 1.2, 95% CI, 0.9-1.5, p = 0.270) was an independent prognostic factor. In subgroup analysis of adenocarcinoma (ADC), survival analyses suggested that group C predicted a worse prognosis. Multivariate analysis of ADC indicated that group C was an independent adverse prognostic factor (HR = 1.9, 95% CI, 1.4-2.7, p < 0.001). Conclusions: Combined elevated preoperative and postoperative CEA is an independent adverse prognostic factor for stage I-III lung adenocarcinoma. Additionally, routine perioperative detection of serum CEA can yield valuable prognostic information for patients after lung cancer surgery.
引用
收藏
页数:11
相关论文
共 34 条
  • [1] [Anonymous], 1997, AM J RESP CRIT CARE, V156, P320
  • [2] Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer
    Chen, Zhong-qing
    Huang, Ling-sha
    Zhu, Bo
    [J]. DISEASE MARKERS, 2018, 2018
  • [3] High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer
    Duan, X.
    Cui, Y.
    Li, H.
    Shi, G.
    Wu, B.
    Liu, M.
    Chang, D.
    Wang, T.
    Kong, Y.
    [J]. INDIAN JOURNAL OF CANCER, 2015, 52 (07) : 158 - 163
  • [4] Foa P, 1999, ANTICANCER RES, V19, P3613
  • [5] CARCINOEMBRYONIC ANTIGEN AND PROGNOSIS AFTER RADICAL SURGERY FOR LUNG-CANCER - IMMUNO-CYTOCHEMICAL LOCALIZATION AND SERUM LEVELS
    FORD, CHJ
    STOKES, HJ
    NEWMAN, CE
    [J]. BRITISH JOURNAL OF CANCER, 1981, 44 (02) : 145 - 153
  • [6] Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer
    Hanagiri, Takeshi
    Sugaya, Masakazu
    Takenaka, Masaru
    Oka, Sohich
    Baba, Tetsuro
    Shigematsu, Yoshiki
    Nagata, Yoshika
    Shimokawa, Hidehiko
    Uramoto, Hidetaka
    Takenoyama, Mitsuhiro
    Yasumoto, Kosei
    Tanaka, Fumihiro
    [J]. LUNG CANCER, 2011, 74 (01) : 112 - 117
  • [7] Prognostic value of serum tumor markers in patients with lung cancer
    Hatzakis, KD
    Froudarakis, ME
    Bouros, D
    Tzanakis, N
    Karkavitsas, N
    Siafakasa, NM
    [J]. RESPIRATION, 2002, 69 (01) : 25 - 29
  • [8] Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma
    Higashi, Kotaro
    Sakuma, Tsutomu
    Ito, Kengo
    Niho, Seiji
    Ueda, Yoshimichi
    Kobayashi, Takeshi
    Sekiguchi, Ryuzo
    Takahashi, Tomoko
    Kato, Takashi
    Tonami, Hisao
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (03) : 373 - 381
  • [9] PREOPERATIVE CARCINOEMBRYONIC ANTIGEN LEVEL AS A PROGNOSTIC INDICATOR IN RESECTED PRIMARY LUNG-CANCER
    ICARD, P
    REGNARD, JF
    ESSOMBA, A
    PANEBIANCO, V
    MAGDELEINAT, P
    LEVASSEUR, P
    [J]. ANNALS OF THORACIC SURGERY, 1994, 58 (03) : 811 - 814
  • [10] Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome
    Konishi, Tsuyoshi
    Shimada, Yoshifumi
    Hsu, Meier
    Tufts, Lauren
    Jimenez-Rodriguez, Rosa
    Cercek, Andrea
    Yaeger, Rona
    Saltz, Leonard
    Smith, J. Joshua
    Nash, Garrett M.
    Guillem, Jose G.
    Paty, Philip B.
    Garcia-Aguilar, Julio
    Gonen, Mithat
    Weiser, Martin R.
    [J]. JAMA ONCOLOGY, 2018, 4 (03) : 309 - 315